Efficacy and safety of fruquintinib in the treatment of colorectal cancer: a systematic review and meta-analysis of studies in China.

ABSTRACT:

Objectives

To evaluate fruquintinib's efficacy and safety in the treatment of colorectal cancer.

Methods

Studies assessing fruquintinib for colorectal cancer were included. Outcomes were overall survival (OS) and progression-free survival (PFS), and adverse reactions. A random-effects model was employed, and sensitivity analysis assessed the stability of the results and potential heterogeneity. Review Manager 5.4 and STATA 15.0 were used for analysis.

Results

Eleven studies with 2,367 patients were included. Fruquintinib significantly improved OS (HR: 0.69; 95% CI: 0.58, 0.81; P < 0.00001) and PFS (HR: 0.44; 95% CI: 0.30, 0.64; P < 0.0001). No significant increase in adverse events, serious adverse events, fatigue, or hypertension. However, sensitivity analysis sugges

SUBMITTER: Feng Y 

PROVIDER: S-EPMC12454978 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature